Please login to the form below
Eric Cornut appointed EFPIA interim director general
Steps into the role as Richard Bergström leaves the association
The European Federation of Pharmaceutical Industries and Associations (EFPIA) has appointed Eric Cornut as its interim director general, following the resignation of Richard Bergström from the post.
Currently an independent consultant based in Basel, Switzerland, Cornut brings over 25 years of pharmaceutical management experience to the role, including five years as chairman of EFPIA's executive committee.
He most recently served as chief ethics, compliance and policy officer at Novartis, taking up the position in 2014 after a four-year stint as chairman of the board for Novartis Japan.
Having first joined Novartis in 1997 as a general manager in The Netherlands, Cornut has held a number of increasingly senior managerial roles at the Swiss pharma firm, including president of Novartis France, head of Europe and chief commercial officer.
Joe Jiminez, president of EFPIA, said: “Eric brings a wealth of valuable experience, having worked in the pharmaceutical industry for more than 25 years with responsibility for both commercial and policy work.
“I am very pleased that Eric accepted to lead EFPIA ad interim.”
Subscribe to our email news alerts
- Planting the Seeds for Future Women Leaders in Medicine
- FDA approves SpringWork’s Ogsiveo as first therapy for desmoid tumours
- GSK shares positive phase 3 results for Blenrep combination in multiple myeloma
- Stem cell therapy trial shows promising results for treating progressive MS
- Cancer Research UK calls on government to create ten-year cancer plan
- Risk calculator to prevent heart attacks and strokes in type 2 diabetes patients
No results were found
PMHub
Redbow Consulting Group
Redbow Consulting Group is a specialist healthcare management consultancy specialising in business strategy and marketing...
Latest intelligence
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
- The rise of digital healthcare – fuelled by open innovation in healthtech hubs
- How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of drug development...
